Is There a Role for the Incretin System in Blood Pressure Regulation?

被引：0
作者：
Akhilesh Rao
Ravi Nistala
机构：
[1] University of Missouri-Columbia School of Medicine,Division of Nephrology, Department of Internal Medicine
来源：
Current Hypertension Reports | 2014年 / 16卷
关键词：
Incretin; DPP4 inhibitor; Adaptive immunity; eNOS; Blood pressure; T; RAAS; Oxidative stress; Cardiorenal; PPAR;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Incretin-based therapies are now well established for diabetes management and are among the frontline agents for control of hyperglycemia. In addition to their antihyperglycemic effects, evidence is emerging on the role of these agents on blood pressure regulation, cardioprotective and renoprotective properties. Because of the pleiotropic nature of these affects, these agents could offer significant benefits with regards to the cardiorenal metabolic complications that are part of the diabetes and obesity epidemic in the United States and worldwide. We review the various known mechanisms or pathways by which incretin based therapy exerts its regulation of blood pressure with emphasis on novel mechanisms such as inflammation/immunomodulation and oxidative stress.
引用
收藏
相关论文
共 297 条
  • [1] Joffres M(2013)Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study BMJ Open 3 e003423-8
  • [2] Falaschetti E(2013)The immune system: role in hypertension Can J Cardiol 29 543-13
  • [3] Gillespie C(2013)Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male zucker obese rats Endocrinology 154 2501-84
  • [4] Robitaille C(2012)Renal and Cardiac Effects of DPP4 Inhibitors - from Preclinical Development to Clinical Research Kidney Blood Press Res 36 65-57
  • [5] Loustalot F(2007)Biology of incretins: GLP-1 and GIP Gastroenterology 132 2131-13
  • [6] Poulter N(2007)Incretin receptors for glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide are essential for the sustained metabolic actions of vildagliptin in mice Diabetes 56 3006-49
  • [7] Schiffrin EL(2013)Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials Diabetes Obes Metab 15 737-9
  • [8] Aroor AR(2013)Effect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression Am J Hypertens 47 1532-5
  • [9] Sowers JR(2011)Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes Tohoku J Exp Med 223 133-8
  • [10] Bender SB(2008)Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension J Clin Pharmacol 03 592-33
12345678910